Title:
CRYSTAL FORMS OF (2E)-N-[4-[(3-CHLORO-4-FLUOROPHENYL)AMINO]-7-METHOXY-6-QUINAZOLINYL]-4-(1-PIPERIDINYL)-2-BUTENAMIDE, AND PREPARATION METHOD THEREFOR
Document Type and Number:
WIPO Patent Application WO/2021/238835
Kind Code:
A1
Abstract:
The present invention relates to a crystal form C of (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide, and a preparation method therefor and a drug containing same. The crystal form C is an anhydrous substance; and by means of Cu-Kα radiation, the X-ray powder diffraction pattern of the crystal form C has characteristic peaks where the diffraction angle 2θ is 5.6° ± 0.2°, 10.5° ± 0.2°, and 12.8° ± 0.2°. The crystal form C of the present invention is an anhydrous substance, and has obvious advantages in drug development in comparison with existing solvates. In addition, while maintaining good stability, the crystal form C of the present invention has a significantly improved solubility compared with existing solvates.
Inventors:
LU XIA (CN)
FAN XIAOTIAN (CN)
ZHANG XIAOYU (CN)
FAN XIAOTIAN (CN)
ZHANG XIAOYU (CN)
Application Number:
PCT/CN2021/095425
Publication Date:
December 02, 2021
Filing Date:
May 24, 2021
Export Citation:
Assignee:
CRYSTAL PHARMATECH CO LTD (CN)
International Classes:
C07D239/94; A61K31/517; A61P35/00
Foreign References:
| CN107793368A | 2018-03-13 | |||
| CN1972688A | 2007-05-30 | |||
| CN103288759A | 2013-09-11 |
Download PDF: